Jan van de Winkel to deliver the Utrecht Science Lecture during the opening of Utrecht Science Week 2025
We are thrilled to announce that Prof. Dr. Jan van de Winkel, President & CEO of Genmab, will present the keynote opening Utrecht Science Lecture during the 2025 Utrecht Science Week on September 26. As a pioneering scientist and industry leader in antibody-based therapies, Jan van de Winkel has been at the forefront of groundbreaking advancements in immunotherapy, shaping the future of cancer treatment and beyond.
With more than 30 years of experience in therapeutic antibodies, Jan van de Winkel has played a pivotal role in translating cutting-edge science into life-changing medicines. As a co-founder of Genmab, he has led the company’s journey from an ambitious startup to a global end-to-end biotech powerhouse. In addition to his executive role, he holds a professorship in immunotherapy at Utrecht University, contributing to academic research and fostering the next generation of scientific leaders.
In his lecture, titled “Cracking the Code on Cancer and Other Serious Diseases: The Past, Present, and Future of Immunotherapy”, he will explore how immunotherapy is revolutionizing medicine. From early discoveries to today’s breakthroughs in cancer care, he will offer insights into the evolving role of antibody therapies, the next frontiers in biotechnology, and the power of collaboration and AI in driving innovation.
As Utrecht Science Week celebrates its fifth edition, this keynote lecture will highlight Utrecht’s ambition as the “Heart of Health” and the Utrecht Science Park as a unique life sciences ecosystem for cutting-edge research and medical innovation. Join us to gain a front-row perspective on the future of immunotherapy and how partnerships between academia, industry, and healthcare can accelerate progress for patients worldwide.
You can register here.
Biotech companies at Utrecht Science Park Genmab and Merus join forces
The Danish-Dutch biotech company Genmab is acquiring its Dutch counterpart Merus. Both companies have their main facilities next to each other at Utrecht Science Park. Genmab is paying $8 billion (€6.8 billion) for its neighbor, thereby acquiring a promising experimental drug for head and neck cancer and colorectal cancer.
UMC Utrecht develops 3D-printed mold for better treatment of nasal cancer
Researchers at UMC Utrecht have developed an innovative 3D printed mold that makes nasal cancer treatment more accurate and patient-friendly. Thanks to the customized mold, tumors can be irradiated more precisely. This results in less damage to surrounding tissue and faster recovery.
Utrecht Science Park takes a step towards greater liveability with the help of Community Builders
To improve the quality of life and social cohesion at Utrecht Science Park, residents and partners are launching the “Springlevend Utrecht Science Park” program, which will recruit Community Builders from among apartment residents. The Community Builders will promote connection, participation, and neighborhood development. They will do this, in part, by establishing and managing a local meeting space. The housing boards at Utrecht Science Park took an important first step in this direction in May of last year, and this is now being followed up.
Experience Utrecht Science Week, register now
From Friday, September 26th to Sunday, October 5th, Utrecht Science Week takes place. Utrecht Science Park will open its doors to everyone interested in (applied) science. Visitors will have a unique opportunity to discover groundbreaking science and world-class innovation. Registration is free.